| Literature DB >> 23497591 |
Matthew C Exline, Naeem A Ali, Nancy Zikri, Julie E Mangino, Kelly Torrence, Brenda Vermillion, Jamie St Clair, Mark E Lustberg, Preeti Pancholi, Madhuri M Sopirala.
Abstract
INTRODUCTION: We set a goal to reduce the incidence rate of catheter-related bloodstream infections to rate of <1 per 1,000 central line days in a two-year period.Entities:
Mesh:
Year: 2013 PMID: 23497591 PMCID: PMC3733431 DOI: 10.1186/cc12551
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
CLA-BSI incidence rate/1000 patient days, incidence rate ratio (IRR) in the post-intervention period compared to baseline period.
| Surveillance period | Number of CLA-BSI | Central line days | CLA-BSI rate/1000 central line days | IRR (95% CI) | Percentage reduction* | |
|---|---|---|---|---|---|---|
| 30 | 11,317 | 2.65 | NA | NA | NA | |
| 11 | 5,589 | 1.97 | 0.74 (0.37-1.65) | 26% | 0.398 | |
| 3 | 5,682 | 0.53 | 0.20 (0.06-0.65) | 80% (35%-94%) | 0.008 | |
| 14 | 11,271 | 1.24 | 0.47 (0.25-0.88) | 53% (12%-75%) | 0.019 |
*Compared to baseline period. CI, confidence interval; CLA-BSI, central line-associated bloodstream infections; NA, not applicable.
Figure 1Central line-associated bloodstream infections, compliance with central line insertion and dressing maintenance during the study period. NHSN, National Health Safety Network.
Monthly CLA-BSI during the study period, device utilization ratio and organisms causing CLA-BSI in each month.
| Surveillance period | Number of CLA-BSI | Central line days | CLA-BSI rate/1000 central line days | Patient days | Device utilization ratio | Organisms causing CLA-BSI |
|---|---|---|---|---|---|---|
| Jan-08 | 1 | 550 | 1.82 | 700 | 0.79 | VRE |
| Feb-08 | 2 | 547 | 3.66 | 675 | 0.81 | |
| Mar-08 | 3 | 562 | 5.34 | 739 | 0.76 | |
| Apr-08 | 1 | 470 | 2.13 | 661 | 0.71 | Group B |
| May-08 | 1 | 468 | 2.14 | 668 | 0.70 | Methicillin-resistant |
| Jun-08 | 1 | 478 | 2.09 | 629 | 0.76 | |
| Jul-08 | 0 | 351 | 0.00 | 626 | 0.56 | |
| Aug-08 | 1 | 340 | 2.94 | 683 | 0.50 | |
| Sep-08 | 0 | 360 | 0.00 | 649 | 0.55 | |
| Oct-08 | 0 | 510 | 0.00 | 691 | 0.74 | |
| Nov-08 | 1 | 518 | 1.93 | 696 | 0.74 | |
| Dec-08 | 2 | 514 | 3.89 | 699 | 0.74 | |
| Jan-09 | 2 | 461 | 4.34 | 700 | 0.66 | |
| Feb-09 | 1 | 474 | 2.11 | 634 | 0.75 | |
| Mar-09 | 4 | 568 | 7.04 | 721 | 0.79 | |
| Apr-09 | 0 | 417 | 0.00 | 639 | 0.65 | |
| May-09 | 1 | 394 | 2.54 | 644 | 0.61 | |
| Jun-09 | 0 | 358 | 0.00 | 626 | 0.57 | |
| Jul-09 | 3 | 389 | 7.71 | 673 | 0.58 | |
| Aug-09 | 2 | 513 | 3.90 | 684 | 0.75 | |
| Sep-09 | 0 | 436 | 0.00 | 661 | 0.66 | |
| Oct-09 | 1 | 505 | 1.98 | 699 | 0.72 | |
| Nov-09 | 1 | 569 | 1.76 | 679 | 0.84 | |
| Dec-09 | 2 | 565 | 3.54 | 728 | 0.78 | |
| Jan-10 | 0 | 468 | 0.00 | 678 | 0.69 | |
| Feb-10 | 0 | 411 | 0.00 | 626 | 0.66 | |
| Mar-10 | 2 | 457 | 4.38 | 623 | 0.73 | VRE |
| Apr-10 | 2 | 386 | 5.18 | 565 | 0.68 | Methicillin-resistant |
| May-10 | 0 | 480 | 0.00 | 615 | 0.78 | |
| Jun-10 | 2 | 479 | 4.18 | 612 | 0.78 | |
| Jul-10 | 0 | 468 | 0.00 | 654 | 0.72 | |
| Aug-10 | 1 | 478 | 2.09 | 627 | 0.76 | VRE |
| Sep-10 | 0 | 423 | 0.00 | 626 | 0.68 | |
| Oct-10 | 2 | 534 | 3.75 | 711 | 0.75 | VRE |
| Nov-10 | 2 | 532 | 3.76 | 679 | 0.78 | VRE |
| Dec-10 | 0 | 473 | 0.00 | 620 | 0.76 | |
| Jan-11 | 0 | 485 | 0.00 | 712 | 0.68 | |
| Feb-11 | 1 | 485 | 2.06 | 647 | 0.75 | VRE |
| Mar-11 | 2 | 535 | 3.74 | 709 | 0.75 | VRE |
| Apr-11 | 0 | 501 | 0.00 | 641 | 0.78 | |
| May-11 | 0 | 461 | 0.00 | 677 | 0.68 | |
| Jun-11 | 0 | 448 | 0.00 | 621 | 0.72 | |
| Jul-11 | 0 | 351 | 0.00 | 655 | 0.54 | |
| Aug-11 | 0 | 454 | 0.00 | 690 | 0.66 | |
| Sep-11 | 0 | 543 | 0.00 | 705 | 0.77 | |
| Oct-11 | 0 | 473 | 0.00 | 677 | 0.70 | |
| Nov-11 | 0 | 473 | 0.00 | 653 | 0.72 | |
| Dec-11 | 0 | 473 | 0.00 | 704 | 0.67 | |
CLA-BSI, central line-associated bloodstream infections.
Figure 2Intensive care unit layout; four patients with VRE central line-associated bloodstream infection were located in two rooms of pod B - two in one room and two in another room. One patient each was located in each of the other pods.
Figure 3Rep-PCR analysis of VRE isolates from blood cultures and environmental cultures related to patients with VRE CLA-BSI. CLA-BSI, central line-associated blood stream infections; P, pattern number; VRE, vancomycin-resistant Enterococcus faecium. Control (row 19) = E.faecalis ATCC™ 51299 control strain.